Therapeutic methods using tolerogenic peptides

A specific dose escalation regimen for tolerogenic peptides effectively induces immune tolerance, addressing the inefficiencies of current treatments by reducing new lesions and extending the duration of therapeutic effects in autoimmune and hypersensitivity disorders.

JP7591017B2Active Publication Date: 2024-11-27WORG PHARM (ZHEJIANG) CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022185110
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-01-04
Filing Date
2022-11-18
Publication Date
2024-11-27
Estimated Expiration
2038-01-04

Smart Images

  • Figure 0007591017000010
    Figure 0007591017000010
  • Figure 0007591017000011
    Figure 0007591017000011
  • Figure 0007591017000001
    Figure 0007591017000001
Patent Text Reader

Abstract

The present invention provides therapeutic methods using tolerogenic peptides that can be used to treat or prevent conditions associated with abnormal, hypersensitive, or pathological immune responses to endogenous or exogenous proteins that result in loss of immune tolerance. In particular, the present invention relates to dosing regimens for tolerogenic peptides. [Solution] A method for treating or preventing a condition associated with abnormal immune tolerance (autoimmune disease) in a subject, comprising administering to a patient a tolerogenic peptide using a dose escalation protocol starting on day 1 with a first dose of about 15 to about 40 μg, and ending on day 126 ± day 7 with a tenth dose of about 600 to 1500 μg.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to therapeutic methods using tolerogenic peptides, in particular to dosing regimens for tolerogenic peptides, which may be used to treat or prevent conditions associated with abnormal, hypersensitive, or pathological immune responses to endogenous or exogenous proteins that result in loss of immune tolerance. [Background technology]

[0002] The immune system is the system within an organism that prevents disease. To function properly, the immune system must detect a wide variety of pathogens, from viruses to parasites, and distinguish them from the organism's own healthy tissue.

[0003] However, while an immunological response can be elicited against foreign antigens, it is undesirable for the immune response to be elicited from an organism's own "self" tissues. In order to prevent aberrant or pathological immune responses, the phenomenon of "immune tolerance" or "immunological tolerance" has developed.

[0004] Immune tolerance refers to a state in which the immune system does not respond to substances or tissues that have the ability to elicit an immune response. The term "immune tolerance" encompasses a range of physiological mechanisms by which the body reduces or eliminates immune responses to specific agents. It is used to describe the phenomenon that underpins the discrimination between self and non-self, inhibits allergic reactions, tolerates chronic infections instead of rejection and elimination, and prevents attack of the fetus by the maternal immune system.

[0005] Natural or "self" tolerance is the lack of attacking the body's own proteins and other antigens. If the immune system reacts to "self", autoimmune disease can result. Thus, there are situations in which immune tolerance may not function normally and aberrant immune tolerance may occur. For example, in autoimmune conditions such as systemic lupus erythematosus (SLE), the body does not correctly distinguish between self and non-self antigens, i.e., there is imprecise or aberrant immune tolerance in that the individual lacks immune tolerance to its own self-antigens.

[0006] Induced tolerance is the deliberate manipulation of the immune system to produce tolerance to foreign antigens. For example, it is important to prevent unpleasant or dangerous allergic reactions to foods (e.g., peanuts), insect stings, and grass pollen (hay fever).

[0007] Furthermore, induced tolerance is important to allow transplanted organs (eg, kidney, heart, liver) to survive in the new recipient; thus, avoiding graft rejection.

[0008] Immunological tolerance is not simply the inability to recognize an antigen; it is an active response to specific epitopes and is as specific as an immune response can be.

[0009] Thus, if immune tolerance does not function correctly, this can have pathological consequences.

[0010] In this regard, it has been shown that it is possible to induce immunological tolerance to specific peptide epitopes by administration of the peptide epitopes in soluble form. In a typical adaptive immune response, T lymphocytes recognize internal epitopes of protein antigens. Antigen-presenting cells (APCs) take up protein antigens and cleave them into short peptide fragments.

[0011] Peptides can bind to major histocompatibility complex (MHC) class I or II molecules intracellularly and be transported to the cell surface. When presented on the cell surface together with MHC molecules, the peptides can be recognized by T cells (via the T cell receptor (TCR)), in which case the peptides are T cell epitopes. Such peptide-based epitopes can be used to induce immunological tolerance.

[0012] Indeed, administration of soluble peptide antigens has been demonstrated as an effective means of preventing disease in experimental autoimmune encephalomyelitis (EAE - a model of multiple sclerosis (MS)) (Metzler and Wraith (1993) Int. Immunol. 5:1159-1165; Liu and Wraith (1995) Int. Immunol. 7:1255-1263; Anderton and Wraith (1998) Eur. J. Immunol. 28:1251-1261); as well as in experimental models of arthritis, diabetes and uveoretinitis (reviewed in Anderton and Wraith (1998) supra). It has also been demonstrated as a means of treating ongoing disease in EAE (Anderton and Wraith (1998) supra).

[0013] The use of tolerogenic peptides to treat or prevent disease has attracted much attention. One reason for this is that it has been shown that certain tolerogenic epitopes can down-regulate T cell responses to different antigens in the same tissue. This phenomenon, known as "bystander suppression", means that it should be possible to use a particular tolerogenic peptide to induce tolerance to more than one epitope (preferably all epitopes) in a given antigen, and more than one antigen for a given disease (Anderton and Wraith (1998) supra). This makes it unnecessary to identify all pathogenic antigens in a particular disease.

[0014] Peptides are also a good choice for therapy due to their relatively low cost and the fact that peptide analogues can be produced with altered immunological properties. Peptides can therefore be modified to alter their interactions with MHC or TCR. Summary of the Invention

[0015] The present invention relates to specific dosing regimens for tolerogenic peptides or combinations of tolerogenic peptides that may be used in the treatment or prevention of diseases or conditions associated with abnormal, hypersensitive, or pathological immune responses to endogenous or exogenous proteins that result in loss of immune tolerance, administered in specific amounts and at specific times as described herein.

[0016] The inventors have surprisingly found that certain slow dose escalation protocols show better efficacy than shorter / faster dose escalation protocols. As discussed in the Examples, a slower dose escalation protocol with four doses over eight weeks before the maximum dose was administered resulted in better efficacy (78% reduction in new lesion count overall) than a shorter dose escalation protocol with two doses over four weeks before the maximum dose was administered (54% reduction in new lesion count overall).

[0017] Furthermore, the inventors have surprisingly found that extending the administration of the maximum dose improves sustained inhibition of new lesions after the last dose, i.e., efficacy is extended after administration of the last dose.

[0018] The present invention therefore includes the combination of a longer dose escalation protocol combined with administration of an extended maximum dose.

[0019] The present invention therefore provides a method of treating or preventing a condition associated with aberrant or pathological immune tolerance in a subject, comprising administering to the subject a tolerogenic peptide in a dose: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 300–1800 μg; Day 70 ± 7: 6th dose of approximately 300–1800 μg; Day 84 ± 7: 7th dose of approximately 300–1800 μg; Day 98 ± 7: 8th dose of approximately 300–1800 μg; Day 112 ± 7: 9th dose of approximately 300 to 1800 μg; and Day 126 ± 7: 10th dose of approximately 300–1800 μg.

[0020] In one embodiment of the invention described herein, the fifth to tenth doses may be about 600 to 1500 μg.

[0021] The reference "± 7 days" is intended to relate to the specified day (i.e., the specified day after the first peptide administration, considered as day 1), and administration may occur up to 7 days before, including, or up to 7 days after the specified day. Thus, administration may occur 7, 6, 5, 4, 3, 2, or 1 day before, or 1, 2, 3, 4, 5, 6, or 7 days after, the specified day.

[0022] In one embodiment of the invention described herein, the reference to "±7 days" is preferably "±3 days." That is, administration may occur up to 3 days before, including, or up to 3 days after the specified date. Thus, administration may occur 3, 2, or 1 day before, or 1, 2, or 3 days after, the specified date.

[0023] In a preferred embodiment of the invention, the method of treating or preventing a condition associated with aberrant or pathological immune tolerance in a subject comprises administering to the patient a tolerogenic peptide in the following doses: Day 1: first dose of about 25 μg; Day 14: second dose of approximately 50 μg; Day 28: third dose of approximately 100 μg; Day 42: fourth dose of approximately 400 μg; Day 56: 5th dose of approximately 800 μg; Day 70: sixth dose of approximately 800 μg; Day 84: 7th dose of approximately 800 μg; Day 98: eighth dose of approximately 800 μg; Day 112: a 9th dose of about 800 μg; and Day 126: 10th dose of approximately 800 μg.

[0024] In one embodiment, the fifth to tenth doses may instead be about 400 μg.

[0025] In an alternative embodiment, the fifth through tenth doses may instead be about 1600 μg.

[0026] Thus, in one embodiment of the present invention, a method for treating or preventing a condition associated with aberrant or pathological immune tolerance in a subject comprises administering to the patient a tolerogenic peptide in the following doses: Day 1: First dose of approximately 25 μg; Day 14: second dose of approximately 50 μg; Day 28: third dose of approximately 100 μg; Day 42: fourth dose of approximately 400 μg; Day 56: 5th dose of approximately 400 μg; Day 70: 6th dose of approximately 400 μg; Day 84: 7th dose of approximately 400 μg; Day 98: 8th dose of approximately 400 μg; Day 112: a 9th dose of about 400 μg; and Day 126: 10th dose of approximately 400 μg.

[0027] In a further embodiment of the invention, a method for treating or preventing a condition associated with aberrant or pathological immune tolerance in a subject comprises administering to the patient a tolerogenic peptide in the following doses: Day 1: First dose of approximately 25 μg; Day 14: second dose of approximately 50 μg; Day 28: third dose of approximately 100 μg; Day 42: fourth dose of approximately 400 μg; Day 56: 5th dose of approximately 1600 μg; Day 70: 6th dose of approximately 1600 μg; Day 84: 7th dose of approximately 1600 μg; Day 98: 8th dose of approximately 1600 μg; Day 112: a 9th dose of about 1600 μg; and Day 126: 10th dose of approximately 1600 μg.

[0028] Any teachings herein relating to the "method" of the present invention are equally applicable to the above-mentioned "uses" encompassed by the present invention.

[0029] In a further embodiment of the invention described herein, an eleventh dose of about 300-1800 μg, preferably about 600-1500 μg, preferably about 1200 μg, more preferably about 400, 800 or 1600 μg is administered on day 140 ± 7, preferably on day 140 ± 3, more preferably on day 140. In a preferred embodiment, the dose is about 800 μg.

[0030] In an even more preferred embodiment, a twelfth dose of about 300-1800 μg, preferably about 600-1500 μg, preferably about 1200 μg, more preferably about 400, 800 or 1600 μg is administered on day 154 ± 7, preferably on day 154 ± 3, more preferably on day 154. In a preferred embodiment, the dose is about 800 μg.

[0031] In a further preferred embodiment, a thirteenth dose of about 300-1800 μg, preferably about 600-1500 μg, preferably about 1200 μg, more preferably about 400, 800 or 1600 μg is administered on day 168 ± 7, preferably on day 168 ± 3, more preferably on day 168. In a preferred embodiment, the dose is about 800 μg.

[0032] In a further preferred embodiment, a 14th dose of about 300-1800 μg, preferably about 600-1500 μg, preferably about 1200 μg, more preferably about 400, 800 or 1600 μg is administered on day 182 ± 7, preferably on day 182 ± 3, more preferably on day 182. In a preferred embodiment, the dose is about 800 μg.

[0033] Additional doses as described above can be administered as needed, for example, for a period of 1 month to 20 years, such as 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, or 20 years.

[0034] Alternatively, the present invention provides a tolerogenic peptide for use in the treatment or prevention of a condition associated with aberrant or pathological immune tolerance in a subject, the tolerogenic peptide being for administration in the following dose: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600-1500 μg; and Day 126 ± 7: 10th dose of approximately 600–1500 μg.

[0035] In one embodiment of the invention described herein, the fifth to tenth doses may be about 600 to 1500 μg.

[0036] The present invention also relates to the use of a tolerogenic peptide in the manufacture of a medicament for use in the treatment or prevention of a condition associated with aberrant or pathological immune tolerance, said medicament being for administration in the following dose: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 300–1800 μg; Day 70 ± 7: 6th dose of approximately 300–1800 μg; Day 84 ± 7: 7th dose of approximately 300–1800 μg; Day 98 ± 7: 8th dose of approximately 300–1800 μg; Day 112 ± 7: 9th dose of approximately 300 to 1800 μg; and Day 126 ± 7: 10th dose of approximately 300–1800 μg.

[0037] In one embodiment of the invention described herein, the fifth to tenth doses may be about 600 to 1500 μg.

[0038] Any teachings herein relating to the "method" of the present invention are equally applicable to the above-mentioned "uses" encompassed by the present invention. [Brief description of the drawings]

[0039] [Figure 1] Figure 1 shows that the number of new Gd lesions measured by MRI was significantly reduced by ATX-MS-1467 treatment in a Phase IB clinical trial (n=21). The dosing protocol for ATX-MS-1467 is also shown (μg). [Diagram 2] FIG. 2 shows the effect of ATX-MS-1467 on new Gd-enhancing lesions measured by MRI in a Phase IIA clinical trial (n=17). The dosing protocol for ATX-MS-1467 is also shown (μg). Means and SEM were back transformed. SEM was calculated from the statistical model. Analyses were performed with a generalized linear mixed model with visit as a fixed factor and patients as subjects. P values ​​are unadjusted Wald tests after fitting the model. *p<0.05, **p<0.01, ***p<0.001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0040] In a first aspect, the present invention relates to a method of treating or preventing a condition associated with aberrant or pathological immune tolerance in a subject, comprising administering to the patient a tolerogenic peptide in a dose of: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 300–1800 μg; Day 70 ± 7: 6th dose of approximately 300–1800 μg; Day 84 ± 7: 7th dose of approximately 300–1800 μg; Day 98 ± 7: 8th dose of approximately 300–1800 μg; Day 112 ± 7: 9th dose of approximately 300 to 1800 μg; and Day 126 ± 7: 10th dose of approximately 300–1800 μg.

[0041] In one embodiment of the invention described herein, the fifth to tenth doses may be about 600 to 1500 μg.

[0042] As discussed above and herein, dosing regimens according to the present invention maximize the effectiveness of dose escalation protocols, improving and prolonging efficacy compared to dosing regimens using shorter dose escalations.

[0043] The present examples show that after the last dose, the dosing regimen according to the present invention extends the time or duration of the observed reduction in clinical effect, e.g., Gd lesion formation. In one embodiment of the invention described herein, the dosing regimen is for extending the time or duration of the reduction in clinical effect. In one embodiment, the reduction in Gd lesion formation can be extended.

[0044] Tolerogenic peptides and tolerance As used herein, the term "tolerogenic" means capable of inducing tolerance to a particular antigen.

[0045] Tolerance is the inability to react to an antigen. Tolerance to self-antigens is an essential feature of the immune system, and its loss can lead to autoimmune disease. The adaptive immune system must maintain the ability to react to a wide variety of infectious agents while avoiding autoimmune attacks of self-antigens contained within its own tissues. This is controlled in large part by the susceptibility of immature T lymphocytes to apoptotic cell death in the thymus (central tolerance). However, not all self-antigens are detected in the thymus, and therefore the death of autoreactive thymocytes remains incomplete, which can result in, for example, autoimmune disorders.

[0046] There are also mechanisms by which tolerance can be acquired by mature autoreactive T lymphocytes in peripheral tissues (peripheral tolerance). A review of the mechanisms of central and peripheral tolerance is given in Anderton et al. (1999) (Immunological Reviews 169:123-137).

[0047] Tolerance may result from or be characterized by the induction of anergy in at least some CD4+ T cells. To activate T cells, peptides must bind to "professional" APCs that are capable of delivering two signals to the T cells. The first signal (signal 1) is delivered by the MHC-peptide complex on the cell surface of the APC and is received by the T cell via the TCR. The second signal (signal 2) is delivered by costimulatory molecules on the surface of the APC, such as CD80 and CD86, and is received by CD28 on the surface of the T cell. It is hypothesized that when T cells receive signal 1 in the absence of signal 2, they are not activated and are in fact anergic. Anergic T cells are refractory to subsequent antigen challenge and may be capable of suppressing other immune responses. Anergic T cells are thought to be involved in mediating T cell tolerance.

[0048] Apitopes are tolerogenic peptides In one aspect of the invention, the tolerogenic peptide is an apitope.

[0049] As discussed above, T lymphocytes can recognize internal epitopes of protein antigens. Antigen presenting cells (APCs) take up protein antigens and break them down into short peptide fragments. Peptides can bind to major histocompatibility complex (MHC) molecules intracellularly and be transported to the cell surface. When presented on the cell surface together with MHC molecules, peptides can be recognized by T cells (via the T cell receptor (TCR)), in which case the peptide is a T cell epitope.

[0050] We have previously shown that peptide epitopes can induce immunological tolerance if they are of appropriate size to be presented by immature APCs without antigen processing (WO 02 / 16410, herein incorporated by reference).

[0051] Epitopes that do not require further processing are capable of inducing tolerance and have been named by the inventors as "apitopes" (Antigen Processing Independent epiTOPES).

[0052] ANTIGEN PROCESSING INDEPENDENT PRESENTATION SYSTEMS (APIPS) Tolerogenic peptides or apitopes can therefore bind to MHC molecules in vitro and be presented to T cells without antigen processing.

[0053] A "processing-free" system can be used to test whether a peptide can bind to an MHC molecule without undergoing antigen processing. Such a system can present antigens to T cells via MHC molecules, but should not be able to process the antigen. Thus, an antigen processing-independent presentation system (APIPS) can be used to test whether a peptide can bind to an MHC molecule in vitro and be presented to T cells without undergoing antigen processing.

[0054] Examples of APIPS include: a) Fixed APCs (with or without antibodies against CD28) b) lipid membranes containing class I or II MHC molecules (with or without antibodies against CD28), and c) Purified native or recombinant MHC in plate-bound form (with or without antibodies against CD28) Includes:

[0055] For example, in tests to determine the minimal epitope within a polypeptide, it is known to use fixed APCs to determine T cell responses by measuring responses to truncated peptides (Fairchild et al. (1996) Int. Immunol. 8:1035-1043). APCs can be fixed, for example, with formaldehyde (usually paraformaldehyde) or glutaraldehyde.

[0056] The lipid membranes (which may be planar membranes or liposomes) may be prepared using artificial lipids or may be plasma membrane / microsomal fractions derived from APCs.

[0057] In use, the APIPS can be added to the wells of a tissue culture plate. Peptide antigen is then added and binding of the peptide to the MHC portion of the APIPS is detected by the addition of selected T cell lines or clones. Activation of the T cell lines or clones can be achieved by any method known in the art, e.g. 3It can be measured via 3H-thymidine incorporation or cytokine secretion.

[0058] If a peptide can be presented to T cells by APIPS, it can bind to an MHC molecule without being subjected to antigen processing and is an apitope.

[0059] Without wishing to be bound by theory, it is hypothesized that peptides that require processing before they can be presented with MHC molecules will not induce tolerance because they must be processed by mature antigen-presenting cells. Mature antigen-presenting cells (such as macrophages, B cells and dendritic cells) can perform antigen processing but can also transmit both signals 1 and 2 to T cells, resulting in T cell activation. On the other hand, apitopes will be able to bind to class II MHC on immature APCs. Thus, they will be presented to T cells without costimulation, resulting in T cell anergy and tolerance.

[0060] Of course, apitopes can also bind to MHC molecules on the cell surface of mature APCs. However, the immune system contains a larger number of immature APCs than mature APCs (it has been suggested that less than 10% of dendritic cells are activated, Summers et al. (2001) Am. J. Pathol. 159: 285-295). Thus, the default view for apitopes would be anergy / tolerance rather than activation.

[0061] Induction of tolerance by inhalation or intradermal or subcutaneous administration of peptides has been shown to reduce the proliferation of antigen-specific CD4+ T cells. In addition, production of IL-2, IFN-γ, and IL-4 by these cells is downregulated, but IL-10 production is increased. Neutralization of IL-10 in mice in a state of peptide-induced tolerance has been shown to completely restore susceptibility to disease. Regulatory cell populations have been proposed to persist in the tolerant state producing IL-10 and mediating immune regulation (Burkhart et al. (1999) Int. Immunol. 11:1625-1634).

[0062] Thus, the induction of tolerance can be monitored by a variety of methods, including: (a) a reduced susceptibility to contracting a disease for which the peptide is a target epitope in vivo; (b) induction of anergy in CD4+ T cells, which can be detected by subsequent in vitro antigen challenge; (c) Changes in CD4+ T cell populations, including: (i) Decreased proliferation; (ii) downregulation of IL-2, IFN-γ, and IL-4 production; and (iii) Increased production of IL-10.

[0063] Identification of peptides containing T cell epitopes There are many methods known in the art for identifying T cell epitopes within a given antigen.

[0064] Naturally processed epitopes can be identified by mass spectrophotometric analysis of peptides eluted from antigen-loaded APCs. These are APCs that have been induced to take up the antigen or forced to produce the protein intracellularly by transformation with the appropriate gene. Typically, APCs are incubated in solution or, appropriately, with a protein that targets the APC cell surface. After incubation at 37° C., the cells are lysed in detergent and the class II protein is purified, for example, by affinity chromatography.

[0065] By treating the purified MHC with an appropriate chemical medium (e.g., acidic conditions), peptides are eluted from the MHC. This pool of peptides is separated and the properties are compared to peptides from similarly treated control APCs. Peaks unique to cells expressing / fed with the protein are analyzed (e.g., by mass spectrometry) and peptide fragments are identified. This procedure usually produces information about the range of peptides (usually found in "nested sets") that are generated from a particular antigen by antigen processing.

[0066] Another method to identify epitopes is to screen a synthetic library of overlapping and antigen-spanning peptides in an in vitro assay. For example, peptides 15 amino acids long and overlapping by 5 or 10 amino acids can be used. The peptides are tested in an antigen-presenting system that includes antigen-presenting cells and T cells. For example, the antigen-presenting system can be a preparation of mouse splenocytes, a sample of human cells from tonsils or PBMCs. Alternatively, the antigen-presenting system can include a specific T cell line / clone and / or a specific antigen-presenting cell type.

[0067] T cell activation can be measured by T cell proliferation (e.g., using H-thymidine incorporation) or cytokine production. Activation of T-type CD4+ T cells can be detected, for example, by IFNγ production, which can be detected by standard methods such as an ELISPOT assay.

[0068] Overlapping peptide testing usually indicates the region of the antigen where the epitope is located. The minimal epitope for a particular T cell can then be assessed by measuring the response to truncated peptides. For example, if responses are obtained to peptides containing 1-15 residues in an overlapping library, a set of truncated ends (i.e., 1-14, 1-13, 1-12, etc., and 2-15, 3-15, 4-15, etc.) can be used to identify the minimal epitope.

[0069] peptide The term "peptide" is used in its conventional sense to mean a series of residues, typically L-amino acids, linked together by peptide bonds, typically between the α-amino and carboxyl groups of adjacent amino acids. The term includes modified peptides and synthetic peptide analogs.

[0070] Peptides for use according to the invention may be of any length that is capable of binding to an MHC molecule without further processing.

[0071] Peptides that bind to MHC class I molecules are typically 7-13, and more commonly 8-10 amino acids long. Peptide binding is stabilized at its two ends by contacts between atoms of the peptide backbone and invariant sites in the peptide-binding groove of all MHC class I molecules. There are invariant sites at both ends of the groove that bind the amino and carboxy termini of the peptide. Variations in peptide length are often accommodated by twisting of the peptide backbone at proline or glycine residues, which provide the required flexibility.

[0072] Peptides that bind to MHC class II molecules are typically 8-20 amino acids long, more commonly 10-17 amino acids long, but can be much longer. These peptides exist in a conformation that stretches along the MHC II peptide-binding groove, which is open at both ends (unlike the MHC class I peptide-binding groove). The peptides are held in place primarily by main-chain atomic contacts with conserved residues that line the peptide-binding groove. In one embodiment, the peptides can be 9-30 amino acids long.

[0073] Peptides for use according to the present invention can be produced using chemical methods (Peptide Chemistry, A practical Textbook. Mikos Bodansky, Springer- Verlag, Berlin). For example, peptides can be synthesized by solid phase methods (Roberge JY et al. (1995) Science 269: 202-204), cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, WH Freeman and Co, New York NY). Automated synthesis can be achieved, for example, using an ABI 43 1A peptide synthesizer (Perkin Elmer) according to the instructions provided by the manufacturer.

[0074] Alternatively, peptides can be produced by recombinant means or by cleavage from a longer polypeptide. For example, peptides can be obtained by cleavage from a target antigen. The composition of the peptide can be confirmed by amino acid analysis or sequencing (e.g., Edman degradation).

[0075] In a preferred embodiment, the peptide can be derived from a target antigen. A target antigen is a molecule (e.g., a protein or glycoprotein) that is processed by APCs and recognized by T cells during the course of a disease. The target antigen will of course depend on the disease of interest. Preferably, the peptide can be derived from a fragment of the antigen that is generated by natural processing of the antigen by APCs.

[0076] Examples of suitable peptides for use according to the present invention are known in the art. For example, WO 2009 / 071886, WO 2014 / 072958 and WO 2010 / 133834 (all of which are incorporated herein by reference) relate to tolerogenic peptides derived from factor VIII protein that have utility in the treatment of hemophilia. These peptides can be used according to the present invention.

[0077] In one embodiment, the subject may have multiple sclerosis or optic neuritis, and thus the tolerogenic peptide may be derived from myelin basic protein. Myelin basic protein (MBP) is an 18.5 kDa protein that can be isolated from the white matter of the human brain. The mature protein has 170 amino acids, and its sequence is widely available in the literature (see, for example, Chou et al. (1986) J. Neurochem. 46:47-53, FIG. 1; Kamholz et al. (1986), PNAS 83:4962-4966, FIG. 2; U.S. Pat. No. 5,817,629, SEQ ID NO: 1; Roth et al. (1987), J. Neurosci. Res. 17:321-328, FIG. 4; Medeveczky et al. (2006), FEBS Letters 580:545-552, FIG. 3B).

[0078] In particular, the tolerogenic peptide may be selected from: MBP 30-44: H-Pro-Arg-His-Arg-Asp-Thr-Gly-Ile-Leu-Asp-Ser-Ile-Gly-Arg-Phe-NH2 (SEQ ID NO: 1) MBP 83-99: H-Glu-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-NH2 (SEQ ID NO: 2) MBP 131-145: H-Ala-Ser-Asp-Tyr-Lys-Ser-Ala-His-Lys-Gly-Phe-Lys-Gly-Val-Asp-NH2 (SEQ ID NO: 3); and MBP 140-154: H-Gly-Phe-Lys-Gly-Val-Asp-Ala-Gln-Gly-Thr-Leu-Ser-Lys-Ile-Phe-NH2 (sequence number 4).

[0079] These peptides are also described in WO 2009 / 056833, which is incorporated herein by reference.

[0080] The MBP 30-44 are also referred to as ATX-MS-01, the MBP83-99 are also referred to as ATX-MS-04, the MBP 131-145 are also referred to as ATX-MS-06, and the MBP 140-154 are also referred to as ATX-MS-07.

[0081] In one preferred embodiment of the invention described herein, all four of MBP 30-44, 83-99, 131-145 and 140-154 are administered to a subject according to the dosing regimen of the invention described herein. In some cases, the combination of all four peptides is referred to herein as "ATX-MS-1467."

[0082] In one embodiment, a composition comprising four peptides is administered to a subject according to the present invention.

[0083] In one embodiment, the subject may have Graves' disease, and thus the tolerogenic peptide may be derived from the thyroid stimulating hormone receptor (TSHR).

[0084] The TSHR is a G protein-coupled receptor on thyroid follicular cells in the thyroid gland that stimulates the production of thyroxine (T4) and triiodothyronine (T3) via the cAMP signaling cascade upon binding of its ligand, thyroid-stimulating hormone (TSH). When the TSHR is internalized, degraded, and presented by APCs, T cells are activated and interact with autoreactive B cells, which then produce stimulatory agonist autoantibodies against the TSHR. Thyroid-stimulating immunoglobulins bind to the same receptor pocket as TSH and activate TSHR-mediated signaling, leading to excess thyroid hormone production from the thyroid gland and thyroid proliferation.

[0085] Thus, in one embodiment, the tolerogenic peptide may be selected from: KKKKYVSIDVTLQQLESHKKK (SEQ ID NO:5) GLKMFPDLTKVYSTD (sequence number 6). KKKKYVSIDVTLQQLESHKKK (SEQ ID NO:5) is also referred to herein as RNB-5D-K1. GLKMFPDLTKVYSTD (SEQ ID NO:6) is also referred to herein as RNB-9B.

[0086] In one embodiment, a composition comprising both peptides of SEQ ID NO:5 and SEQ ID NO:6 is administered to a subject according to the present invention.

[0087] In the composition, the relative ratios of peptides (MBP 30-44:MBP 83-99:MBP 131-145:MBP 140-154 or RNB-5D-K1:RNB-9B) can be about 1:1:1:1 or 1:1 (by weight or molar ratio), respectively. Alternatively, the relative ratio of each peptide can be altered, for example, to target the tolerogenic response to a particular subset of autoreactive T cells or if one peptide is found to be more effective than another in a particular HLA type.

[0088] The terms "MBP 30-44", "MBP 83-99", "MBP 131-145", "MBP 140-154", RNB-5D-K1 and RNB-9B encompass modified peptides. For example, the peptides may be mutated by amino acid insertion, deletion or substitution, so long as the MHC binding specificity of the unmodified peptide is retained along with the ability to be presented to T cells. The peptides may have, for example, 5, 4, 3, 2, 1 or 0 mutations from the unmodified sequence.

[0089] Alternatively (or in addition), modifications may be made without altering the amino acid sequence of the peptide. For example, D-amino acids or other unnatural amino acids may be included, normal amide bonds may be replaced by ester or alkyl backbone bonds, and N- or C-alkyl substituents, side chain modifications, and constraints such as disulfide bridges and side chain amide or ester bonds may be included. Such modifications may increase the in vivo stability and biological lifetime of the peptide.

[0090] Epitope modifications can be made based on predictions for more efficient T cell induction derived using the program "Peptide Binding Predictions" by K. Parker (NIH), available at http: / / www-bimas.dcrt.nih.gov / cgi-bin / molbio / ken_parker_comboform (see also Parker, K. C et al. 1994. J. Immunol. 152:163).

[0091] A peptide for use according to the invention may comprise or consist of an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to any of the peptides of SEQ ID NOs: 1 to 6. In one aspect the peptide has at least 70%, 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any of SEQ ID NOs: 1 to 6.

[0092] Sequence identity can be evaluated by any convenient method. However, to determine the degree of sequence identity between sequences, computer programs that perform multiple alignments of sequences, such as Clustal W (Thompson et al., (1994) Nucleic Acids Res., 22: 4673-4680), are useful. Programs that compare and align pairs of sequences, such as ALIGN (Myers et al., (1988) CABIOS, 4: 1-17), FASTA (Pearson et al., (1988) PNAS, 85:2444-2448; Pearson (1990), Methods Enzymol., 183: 63-98), and Gapped BLAST (Altschul et al., (1997) Nucleic Acids Res., 25: 3389-3402), are also useful for this purpose. In addition, the European Bioinformatics Institute's DALIserver provides structure-based alignments of protein sequences (Holm (1993) J. Mol. Biol., 233: 123-38; Holm (1995) Trends Biochem. Sci., 20: 478-480; Holm (1998) Nucleic Acid Res., 26: 316-9).

[0093] Multiple sequence alignments and percent identity calculations may be determined using standard BLAST parameters (sequences from all available organisms, Blosum 62 matrix, gap costs: existence 11, extension 1).

[0094] Alternatively, the following programs and parameters may be used: Program: Align Plus 4, version 4.10 (Sci Ed Central Clone Manager Professional Suite); DNA comparison: global comparison, Standard Linear Scoring matrix, mismatch penalty = 2, Open gap penalty = 4, Extend gap penalty = 1; Amino acid comparison: global comparison, BLOSUM 62 scoring matrix.

[0095] Thus, variants of a stated or given sequence are included within the scope of the invention so long as the variant retains the functional activity of the parent, i.e., the variant is functionally equivalent, in other words, the variant has or exhibits the activity of the parent peptide as defined herein. Such variants may include amino acid substitutions, additions or deletions (including truncations at one or both termini) of the parent sequence, e.g., one or more, e.g., 1-14 amino acids.

[0096] Also included are functionally equivalent derivatives in which one or more amino acids have been chemically derivatized, e.g., substituted with a chemical group.

[0097] Thus, the peptides of the present invention may comprise portions or fragments of SEQ ID NOs: 1 to 6, provided that the peptides retain the required activity. The fragments or portions of SEQ ID NOs: 1 to 6 may be, for example, 6 to 14 residues in length, such as 6, 7, 8, 9, 10, 11, 12 or 13 residues in length.

[0098] A peptide of the invention may comprise 8 to 30 amino acids, for example 8 to 25 amino acids, 8 to 20 amino acids, 8 to 15 amino acids or 8 to 12 amino acids. In one aspect a peptide of the invention may thus be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length.

[0099] The peptides may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptides), which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acid, or organic acids such as acetic, oxalic, tartaric and maleic acids. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine and procaine.

[0100] WO 2015 / 019302 (herein incorporated by reference) relates to tolerogenic peptides derivable from the human thyroid stimulating hormone receptor (TSHR) that have utility in the treatment of Graves' disease. The peptides described in WO 2015 / 019302 are suitable for use according to the present invention. The peptides described in WO 2016 / 103213 are also suitable for use according to the present invention.

[0101] Target disease The peptides described herein are used in accordance with the present invention to treat or prevent conditions associated with abnormal or pathological immune tolerance, which, as discussed above, is a state in which the immune system does not respond to substances or tissues capable of eliciting an immune response.

[0102] Apitopes for MHC class I can be used, for example, to modulate anti-viral CD8+ responses in a manner that produces tolerance.

[0103] Apitopes for MHC class II are likely to be particularly useful in diseases mediated by CD4+ T cell responses, for example diseases established or maintained by inappropriate or excessive CD4+ T cell responses.

[0104] Such peptides are likely to be particularly useful in the treatment of hypersensitivity disorders. Hypersensitivity reactions include: (i) Allergies, resulting from an inappropriate reaction to a harmless foreign substance; (ii) autoimmune diseases, resulting from a reaction by autoreactive T cells against self-tissue antigens; and (iii) graft rejection, resulting from a reaction to the transplant.

[0105] Examples of allergies include, but are not limited to, hay fever, extrinsic asthma, insect bite and sting allergies, food and drug allergies, allergic rhinitis, bronchial asthma, chronic bronchitis, anaphylactic syndromes, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, Stevens-Johnson syndrome, rhinoconjunctivitis, conjunctivitis, cutaneous necrotizing venulitis, inflammatory lung diseases, and bullous skin diseases.

[0106] Examples of autoimmune diseases include, but are not limited to, rheumatoid arthritis (RA), myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosus (SLE), autoimmune thyroiditis (Hashimoto's thyroiditis), Graves' disease, uveitis (including intermediate uveitis), inflammatory bowel disease, autoimmune uveoretinitis, polymyositis and certain types of diabetes mellitus, systemic vasculitis, polymyositis-dermatomyositis, systemic sclerosis (scleroderma), Sjogren's syndrome, ankylosing spondylitis and related spondyloarthropathy, rheumatic fever, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, inorganic dust pneumoconioses, sarcoidosis, autoimmune hemolytic anemia, immunological platelet disorders, cold diseases such as cryofibrinogenemia, and autoimmune polyendocrinopathy.

[0107] In a preferred embodiment of the invention, the subject has multiple sclerosis and / or optic neuritis. In a preferred aspect, the subject preferably has multiple sclerosis.

[0108] In another preferred embodiment of the invention, the subject has Graves' disease.

[0109] A variety of tissues are commonly transplanted in clinical medicine, including kidney, liver, heart, lung, skin, cornea, and bone marrow. Currently, all transplants except for corneal and some bone marrow transplants usually require long-term immunosuppression.

[0110] Multiple sclerosis Multiple sclerosis (MS) is a chronic inflammatory disease characterized by numerous demyelinating lesions scattered throughout the CNS white matter, occurring at different sites and at different times (McFarlin and McFarland, 1982 New England J. Medicine 307:1183-1188 and 1246-1251).

[0111] The gradual destruction of myelin occurs piecemeal throughout the brain and / or spinal cord, disrupting neural connectivity and leading to muscle weakness, loss of coordination and speech, and vision impairment.

[0112] References herein to multiple sclerosis or MS are intended to encompass the four forms of multiple sclerosis, including relapsing-remitting, primary progressive, secondary progressive and progressive relapsing.

[0113] Relapsing-remitting MS is the most common form, affecting approximately 85% of people who are first diagnosed with the disease and approximately 60% of people living with MS. Most new multiple sclerosis diagnoses are classified as relapsing-remitting, but individuals can develop other forms of the disease over time.

[0114] In relapsing-remitting multiple sclerosis, patients experience periods of active symptoms called relapses followed by symptom-free periods called remissions. Some people with relapsing-remitting multiple sclerosis may go a year or more between relapses, while others may experience more frequent relapses.

[0115] With regard to secondary progressive MS, patients with relapsing-remitting MS usually develop secondary progressive multiple sclerosis about 10-15 years after their initial diagnosis of relapsing-remitting multiple sclerosis. Once diagnosed with secondary progressive multiple sclerosis, people will notice a change in the pattern of their disease. Although some acute attacks (exacerbations) and periods of remission may still occur, they will occur less frequently, recoveries will be less complete, and symptoms will become chronic and gradually worsen over time.

[0116] Approximately 10% of MS patients are diagnosed with primary progressive multiple sclerosis. In this more severe form of multiple sclerosis, the exacerbations or attacks seen in people with relapsing-remitting MS occur rarely, if at all. Instead, MS symptoms worsen over time, gradually leading to disability.

[0117] Progressive relapsing MS is the least common type of multiple sclerosis. Like primary progressive MS, this form of multiple sclerosis is characterized by a gradual worsening of symptoms over time, but patients with this type of MS will also experience exacerbations and remissions. However, unlike relapsing-remitting MS, people with progressive relapsing multiple sclerosis typically do not regain full functionality after a relapse of symptoms. In progressive relapsing MS, disability is caused by a combination of disease progression and incomplete recovery after attacks.

[0118] In one embodiment of the invention described herein, the subject has relapsing MS. The reference "relapsing MS" encompasses patients with relapsing-remitting MS as well as patients who have transitioned from relapsing-remitting MS to secondary progressive MS.

[0119] optic neuritis Optic neuritis (ON) is an inflammation accompanied by demyelination of the optic nerve that supplies the retina of the eye. It is a variable condition that can present with any of the following symptoms: blurred vision, decreased visual acuity, partial or complete loss of color vision, complete or partial blindness, and pain at the back of the eye.

[0120] Optic neuritis is one of the most frequent presenting symptoms of multiple sclerosis and is the most common symptom at the onset of MS, however ON can have causes other than MS, such as ischemic optic neuropathy.

[0121] ON is unilateral (in only one eye) in 70% of cases.

[0122] Most typically, optic neuritis first affects people between the ages of 15 and 50. In this age group, studies have shown that more than 50% of patients will transform into multiple sclerosis within 15 years. As with MS, women are approximately twice as likely as men to present with ON, and the prevalence is higher in whites than in other racial groups.

[0123] The main symptoms of optic neuritis are: Decreased vision (blurred vision); ·Eye pain; · Colour blindness (reduced colour vision); Movement and sound phosphenes (visual flashes of light triggered by eye movement or sound); Uhthoff's symptom, which is worse with fever or extreme fatigue. Treatment of ON with a composition according to the invention may prevent, reduce or ameliorate any of these symptoms. To monitor the progression of ON, visual acuity may be conveniently measured using a Snellen eye chart.

[0124] Graves' disease In one aspect of the invention, the subject has Graves' disease.

[0125] Graves' disease is an autoimmune disorder affecting the thyroid gland. It is characterized by an overactive thyroid gland, which produces excess thyroid hormone and causes the thyroid gland to enlarge (thyroidoma). The resulting state of hyperthyroidism can cause a wide range of neuropsychological and physical symptoms. Graves' disease is the most common cause of hyperthyroidism (60-90% of all cases) and usually appears during middle age, but can also appear in children, adolescents, and the elderly. Graves' disease affects up to 2% of the female population and is 5-10 times more common in women than in men. Pediatric Graves' disease affects approximately 6,000 children in the United States (US) and 6,000 people in the European Union (EU). Graves' disease is also the most common cause of severe hyperthyroidism, which is associated with more clinical signs and symptoms and laboratory abnormalities than milder forms of hyperthyroidism. Graves' disease is associated with a strong genetic component. There are no recent population studies of Graves' disease, but there are a few subpopulation studies of hyperthyroidism, and therefore all estimates of the incidence and prevalence of Graves' disease are approximate. The incidence of hyperthyroidism ranges from 26:100,000 to 93:100,000, with an overall prevalence estimated at 1.3%, with 40% of cases being overt and 60% being subclinical.

[0126] Approximately 30-50% of people with Graves' disease also suffer from Graves' ophthalmopathy (GO), a condition in which one or both eyes bulge. While many cases of GO are mild and self-limited, 20% of cases have significant / moderate-to-severe disease, at least half of these require steroids, and 3-5% of GO patients have painful, vision-threatening disease called thyroid optic neuropathy. Bulging of the eye can cause severe drying of the cornea, as can the inability to close the eyelids at night. Increased pressure on the optic nerve can result in visual field defects and vision loss. GO can also be associated with pretibial myxedema.

[0127] The symptoms and signs of Graves' disease almost entirely result from the direct and indirect effects of hyperthyroidism, with the major exceptions being GO, goiter, and pretibial myxedema. Hyperthyroidism symptoms may include insomnia, hand tremors, hyperkinesia, hair loss, excessive sweating, heat intolerance, and weight loss despite increased appetite. Additional signs are most commonly a diffusely enlarged (usually symmetrical) non-tender thyroid gland, delayed eye closure, excessive tearing due to GO, cardiac arrhythmias, and hypertension. Thyrotoxic patients may experience behavioral and personality changes, such as psychosis, agitation, and depression. With milder hyperthyroidism, patients may experience less obvious signs, such as anxiety, restlessness, irritability, and emotional lability.

[0128] In a preferred embodiment of the invention, the subject of the method is a mammal, preferably a cat, dog, horse, donkey, sheep, pig, goat, cow, mouse, rat, rabbit or guinea pig, but most preferably the subject is a human.

[0129] As defined herein, "treatment" refers to the reduction, alleviation or elimination of one or more symptoms of the condition being treated compared to the symptoms prior to treatment.

[0130] "Prevention" (or prophylaxis) refers to delaying or preventing the onset of symptoms of a condition. Prevention may be complete (so that the condition does not occur) or may be effective only in some individuals or for a limited period of time.

[0131] Dosage regimen The present invention relates to an "escalating dose" regimen in which multiple doses of increasing strength are given to the patient.

[0132] According to the present invention, the following dosing regimen is used: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 300–1800 μg; Day 70 ± 7: 6th dose of approximately 300–1800 μg; Day 84 ± 7: 7th dose of approximately 300–1800 μg; Day 98 ± 7: 8th dose of approximately 300–1800 μg; Day 112 ± 7: 9th dose of approximately 300 to 1800 μg; and Day 126 ± 7: 10th dose of approximately 300–1800 μg.

[0133] In one embodiment of the invention described herein, the fifth to tenth doses may be about 600 to 1500 μg.

[0134] Thus, about 15 to about 40 μg of tolerogenic peptide is administered as a first dose on day 1. In a preferred embodiment, about 25 μg is administered, for example, about 17 to 35, 18 to 33, 20 to 30, 22 to 28, or 24 to 26 μg. In a most preferred embodiment, 25 μg is administered.

[0135] The second dose is administered on day 14 ± 7, preferably on day 3, i.e., each "day" after "day 1" is counted as about 24 hours. In a preferred embodiment, the second dose is administered on day 14.

[0136] The doses may be administered at the same time of day or at different times of day. Preferably, the first, second, third and subsequent doses are administered at the same time of day.

[0137] The second dose is about 35 to about 65 μg of the tolerogenic peptide. In preferred embodiments, the dose is about 37 to 60, 40 to 58, 42 to 56, or 45 to 55 μg. In particularly preferred embodiments, the second dose is about 50 μg, e.g., 45, 46, 47, 48, 49, 51, 52, 43, 54, or 55 μg. In the most preferred embodiments, the second dose is 50 μg.

[0138] The third dose is administered on day 28 ± 7, preferably on day 3, i.e., each "day" counts as about 24 hours after the first dose on "day 1." In a preferred embodiment, the third dose is administered on day 28.

[0139] The third dose is about 80 to about 120 μg of the tolerogenic peptide. In preferred embodiments, the third dose is about 85 to 115, 87 to 113, 90 to 110, 92 to 107, 95 to 105, or 97 to 102 μg. In particularly preferred embodiments, the third dose is about 100 μg, e.g., 95, 96, 97, 98, 99, 101, 102, 103, 104, or 105 μg. In the most preferred embodiments, the third dose is 100 μg.

[0140] The fourth dose is administered on day 42 ± 7, preferably on day 3, i.e., each "day" after "day 1" is counted as approximately 24 hours. In a preferred embodiment, the third dose is administered on day 42.

[0141] The fourth dose is about 300 to about 500 μg of the tolerogenic peptide. In a preferred embodiment, the fourth dose is about 320 to 480, 350 to 450, 365 to 440, 370 to 430, 380 to 420, or 390 to 410 μg. In a particularly preferred embodiment, the fourth dose is about 400 μg, for example, 395, 396, 397, 398, 399, 401, 402, 403, 404, or 405 μg. In a most preferred embodiment, the fourth dose is 400 μg.

[0142] After the fourth dose, subsequent doses of about 300 to about 1800 μg of the tolerogenic peptide are administered approximately every 14 days ± 7, preferably every 3, days. At least six doses of about 300 to about 1800 μg are administered. As discussed herein, the doses of about 300 to about 1800 μg may also be administered more than six times, for example, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses may be administered. As discussed above, the doses may be repeated for periods of, for example, up to 20 years.

[0143] Thus, the interval between doses according to the present invention can be about 14 days or 2 weeks. The interval can be the same throughout the period or can be different. For example, a combination of different intervals can be used, for example, the first subsequent dose can be 14 days apart, while the second subsequent dose can be administered 15 days apart. In the most preferred embodiment, the subsequent doses are administered every 14 days or every 2 weeks.

[0144] Subsequent doses, the 5th to 10th doses (and optionally the 11th, 12th, 13th and 14th doses) are from about 300 to about 1800 μg of tolerogenic peptide. In a preferred embodiment, the 5th to 10th doses (and optionally the 11th, 12th, 13th and 14th doses) are each about 400, 500, 600, 800, 1000, 1200 or 1600 μg, e.g., 400-1600, 600-1200, 600-1000 or 600-800 μg. In one aspect, the 5th to 10th (and optionally 11th to 14th) doses are each about 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600 or 1650 μg. In particularly preferred embodiments, the fifth to tenth (and optionally the eleventh to fourteenth) doses are each about 800 μg, e.g., 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810 or 815 μg. In a most preferred embodiment, the fifth to tenth doses are 800 μg.

[0145] In an alternative embodiment, the fifth through tenth (and optionally the eleventh through fourteenth) doses are each about 400 μg, e.g., 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410 or 415 μg. In a most preferred embodiment, the fifth through tenth doses are 400 μg.

[0146] In an alternative embodiment, the fifth to tenth (and optionally the eleventh to fourteenth) doses are each about 1600 μg, e.g., 1585, 1586, 1587, 1588, 1589, 1590, 1591, 1592, 5193, 194, 1595, 1596, 1597, 1598, 1599, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610 or 1615 μg. In a most preferred embodiment, the fifth to tenth doses are 600 μg.

[0147] In an alternative embodiment of the invention, further doses are administered after the doses discussed above, i.e., the subject may continue to receive doses after the initial dose discussed above.

[0148] Dosages may be adjusted as needed by methods known to those skilled in the art.

[0149] For administration of the peptides described herein in vivo, any mode of administration common or standard in the art may be used, such as oral, intravenous, intramuscular, subcutaneous, sublingual, intranasal, intradermal, suppository routes or implantation.

[0150] In a preferred embodiment of the invention described herein, administration is intradermal, for example by intradermal injection. Intradermal administration can be performed by conventional methods known in the art.

[0151] The method may be carried out multiple times (eg, 2, 3 or more times) after appropriate intervals in its entirety, or parts of the method may be repeated as necessary.

[0152] In one embodiment, the method comprises the steps of: (i) Identifying the antigen for the condition; (ii) identifying a tolerogenic peptide for the antigen; and (iii) administering to the subject a tolerogenic peptide according to the present invention.

[0153] In a further embodiment, the method includes identifying a subject having a condition associated with aberrant or pathological immune tolerance or identifying a subject who is likely to develop a condition associated with aberrant or pathological immune tolerance.

[0154] The peptides may be in the form of compositions comprising one or more pharma- ceutically acceptable diluents, carriers or excipients. These compositions may be formulated in any convenient manner, for example using one or more pharma- ceutically acceptable diluents, carriers or excipients, according to methods and procedures known in the pharmaceutical art.

[0155] The composition may be prepared as an injectable liquid solution or suspension; solid forms suitable for dissolving or suspending in liquid prior to injection may also be prepared. The preparation may also be emulsified, or the peptide may be encapsulated in liposomes. Alternatively, the peptide may be encapsulated in a carrier or bound to the surface of a carrier, such as a nanoparticle. The active ingredient may be mixed with excipients that are pharma- ceutically acceptable and compatible with the active ingredient.

[0156] As used herein, "pharmaceutical acceptable" refers to a component that is compatible with the other components of the composition and physiologically tolerable to the recipient.

[0157] Suitable excipients are, for example, water, saline (eg, phosphate buffered saline), dextrose, glycerol, ethanol, or the like and combinations thereof.

[0158] In addition, if necessary, the composition may contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, and / or pH buffering agents. Buffer salts include phosphates, citrates, and acetates. Hydrochloric acid and / or sodium hydroxide may be used to adjust pH. Disaccharides such as sucrose or trehalose may be used for stabilization.

[0159] The nature of the composition, and of the carrier or excipient materials, etc., may be selected in the usual manner according to the choice and desired route of administration, therapeutic purpose, etc.

[0160] The peptides may be administered in a soluble form, in the absence of an adjuvant.

[0161] We predict that, despite "bystander suppression," it may be necessary to target many different T cell clones to effectively induce tolerance, and therefore multiple peptides, i.e., more than one peptide, may be administered to an individual to prevent or treat disease.

[0162] The pharmaceutical composition may contain, for example, 1 to 50 peptides, preferably 2 to 15 peptides. The peptides may be derived from the same or different target antigens. Preferably, the peptides are all capable of binding to MHC class I or all capable of binding to MHC class II without further processing, i.e., they are apitopes. In a preferred embodiment, all apitopes in the pharmaceutical composition are capable of binding to MHC class I or class II without further processing.

[0163] The pharmaceutical composition may be in the form of a kit for use according to the invention, in which the or each peptide is provided separately for simultaneous, separate or sequential administration.

[0164] Alternatively (or additionally), when the pharmaceutical composition (or any portion thereof) is to be administered in multiple doses, each dose may be individually packaged.

[0165] Pharmaceutical compositions may comprise a therapeutically or prophylactically effective amount of the or each peptide, and optionally a pharma- ceutically acceptable carrier, diluent or excipient.

[0166] In the pharmaceutical compositions of the invention, the or each peptide may also be mixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) or solubilising agent(s). The present invention also provides the following aspects. [1] A method for treating or preventing a condition associated with abnormal immune tolerance (autoimmune disease) in a subject, comprising administering to the patient a tolerogenic peptide in a dose escalation protocol at the following doses: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600-1500 μg; and Day 126 ± 7: 10th dose of approximately 600–1500 μg. [2] The method according to [1], wherein the first dose is about 25 μg, preferably 25 μg. [3] The method according to [1] or [2], wherein the second dose is about 50 μg, preferably 50 μg. [4] The method according to any one of [1] to [3], wherein the third dose is about 100 μg, preferably 100 μg. [5] The method according to any of [1] to [4], wherein the fourth dose is about 400 μg, preferably 400 μg. [6] The method according to any of [1] to [5], wherein an 11th dose of approximately 600 to 1,000 to 1,500 μg is administered on day 140 ± 7. [7] The method according to any of [1] to [6], wherein a 12th dose of approximately 600 to 1500 μg is administered on day 154 ± 7. [8] The method according to any of [1] to [8], wherein a 13th dose of approximately 600 to 1500 μg is administered on day 168±7. [9] The method according to any of [1] to [8], wherein the fifth, sixth, seventh, eighth, ninth and tenth doses, and optionally the eleventh, twelfth and thirteenth doses, are each about 800 μg, preferably 800 μg.

[10] The method according to any of [1] to [9], wherein the peptide is administered intradermally.

[11] The method according to any one of [1] to

[10] , wherein the subject is a human.

[12] The method according to any of [1] to

[11] , wherein the tolerogenic peptide is selected from MBP 30-44 (SEQ ID NO: 1); 83-99 (SEQ ID NO: 2); 131-145 (SEQ ID NO: 3) and 140-154 (SEQ ID NO: 4).

[13] The method according to

[12] , wherein MBP 30-44; 83-99; 131-145 and 140-154 are administered.

[14] The method according to any one of [1] to

[11] , wherein the tolerogenic peptide is selected from RNB-5D-K1 (SEQ ID NO: 5) and RNB-9B (SEQ ID NO: 6).

[15] The method according to

[14] , wherein RNB-5D-K1 (sequence number 5) and RNB-9B (sequence number 6) are administered.

[16] The method according to any one of [1] to

[15] , wherein the condition is a hypersensitivity disorder.

[17] The method according to

[16] , wherein the hypersensitivity disorder is selected from allergy, autoimmune disease, and transplant or graft rejection.

[18] The method according to

[17] , wherein the allergy is selected from hay fever, extrinsic asthma, insect bite and sting allergies, food and drug allergies, allergic rhinitis, bronchial asthma, chronic bronchitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, Stevens-Johnson syndrome, rhinoconjunctivitis, conjunctivitis, cutaneous necrotizing venulitis, inflammatory lung diseases, and bullous skin diseases.

[19] The method according to

[17] , wherein the autoimmune disease is selected from rheumatoid arthritis (RA), myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosus (SLE), autoimmune thyroiditis (Hashimoto's thyroiditis), Graves' disease, uveitis (including intermediate uveitis), inflammatory bowel disease, autoimmune uveoretinitis, polymyositis and certain types of diabetes mellitus, systemic vasculitis, polymyositis-dermatomyositis, systemic sclerosis (scleroderma), Sjogren's syndrome, ankylosing spondylitis and related spondyloarthropathy, rheumatic fever, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, inorganic dust pneumoconioses, sarcoidosis, autoimmune hemolytic anemia, immunological platelet disorders, cold diseases such as cryofibrinogenemia, and autoimmune polyendocrinopathy.

[20] The method according to any of [1] to

[19] , wherein the condition is multiple sclerosis or optic neuritis, preferably multiple sclerosis.

[21] The method according to any of [1] to

[19] , wherein the condition is Graves' disease.

[22] The method according to

[17] , wherein the transplant organ is selected from kidney, liver, heart and lung, skin, cornea and bone marrow, and / or the graft is selected from cornea and bone marrow.

[23] A tolerogenic peptide for use in the treatment or prevention of a condition associated with abnormal immune tolerance, the tolerogenic peptide being for administration by a dose escalation protocol at the following doses: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600-1500 μg; and Day 126 ± 7: 10th dose of approximately 600–1500 μg.

[24] Use of a tolerogenic peptide in the manufacture of a medicament for use in the treatment or prevention of a condition associated with abnormal immune tolerance, optionally wherein the condition is not multiple sclerosis, and the medicament is for administration by a dose escalation protocol at the following doses: Day 1: First dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600-1500 μg; and Day 126 ± 7: 10th dose of approximately 600–1500 μg.

[25] A tolerogenic peptide for use according to

[23] or use of a tolerogenic peptide in the manufacture of a medicament according to

[24] , wherein the dose of the peptide is as defined in any of [2] to [9], the route of administration is as defined in

[10] , the subject is as defined in

[11] , the peptide is as defined in any of

[12] to

[15] , and / or the condition is as defined in any of

[16] to

[22] . EXAMPLES

[0167] The following examples serve to illustrate the invention but should not be construed as limiting it, the invention being directed in particular to the specific embodiments described in these examples.

[0168] <Example 1> HLA DRB1 with relapsing multiple sclerosis * An open-label, dose-escalation evaluation of the effect of ATX MS 1467 on safety, immunology, and imaging-based efficacy biomarkers (gadolinium-enhanced MRI scanning) was performed in 40 patients with 15 positive disease.

[0169] method: A phase I, open-label, dose-escalation study. 8-week escalation period (25, 50, 100, 400, and 800 μg administered at 14±3 day intervals); 6-week full-dose treatment period (five 800 μg doses administered at 14±3 day intervals); 28-week follow-up period (no treatment with study medication). Patients in cohort 1 were treated with intradermal (id) ATX-MS-1467; patients in cohort 2 were treated with subcutaneous (sc) ATX-MS-1467. After the first 10 and 20 patients, respectively, received the final 800 μg dose, the safety data for cohort 1 were combined and subjected to an interim safety review by the Data Monitoring Committee (DMC).

[0170] [Table 1] * Percentages are based on the number of patients in the study population. ** Percentages are based on number of patients in the ITT population. id = intradermal, ITT = intention-to-treat, MRI = magnetic resonance imaging, PP = per protocol, sc = subcutaneous

[0171] Diagnosis and main selection criteria: Diagnosis: RMS as defined by the McDonald criteria and assessed by a neurologist, human lymphocyte antigen (HLA)-DRB1 * 15 positive Key selection criteria: A high baseline level of T cell proliferation in response to MBP, defined as >1000 counts per minute (cpm) and a stimulation index >3 compared to background. Disease duration ≤10 years (from first clinical event) Documented at least one recurrence in the past 12 months or two recurrences within the past 24 months prior to screening. Expanded disability status scale (EDSS) score ≤ 5.5 -Age 18 to 55 at the time of informed consent · Use of contraception for men and women as defined in the protocol. Be willing and able to provide written informed consent.

[0172] Test product, dose and mode of administration: ATX-MS-1467A : 4 mg / mL mixture made of equal amounts of peptides ATX-MS-01, ATX-MS-04, ATX-MS-06 and ATX-MS-07 in phosphate buffered saline (PBS). ATX MS 1467B: 0.5 mg / mL mixture made of equal amounts of peptides ATX-MS-01, ATX-MS-04, ATX-MS-06 and ATX-MS-07 in PBS.

[0173] [Table 2]

[0174] Mode of Administration: Cohort 1:id Cohort 2:sc

[0175] Treatment duration: Patients were scheduled to receive one or two injections of ATX-MS-1467, spaced 14±3 days apart, for 16 weeks.

[0176] Evaluation criteria: Effectiveness Magnetic resonance imaging MRI - new GD enhancing lesions, T2 hyperintense lesions, T1 hypointense lesions. Week -4, Study Day 1; week prior to or week of Week 4 and 8 visits; Week 12, 16, 20, 28, 36, and 48 visits, week prior to all follow-up visits; visit at early discontinuation. MRI was assessed as part of safety and efficacy.

[0177] safety Adverse events (AEs): severity, association with ATX-MS-1467, outcome, action taken, onset, resolution date, and severity. Recorded throughout the study. · Injection site reactions: with all injections. Vital signs: heart rate, systolic and diastolic blood pressure, temperature. At screening, week -4, and at each injection visit. Physical Examination: At Screening, Week -4, and at each injection visit; at early discontinuation visits. 12-lead ECG: at screening and week -4. Neurological Examination: Kurtzke Functional System (KFS) and Kurtzke Expanded Disability Status Scale (EDSS). At Screening, Week -4, Study Day 1, Week 12, all follow-up visits; at early discontinuation visits. Haematology: Red blood cell count, hemoglobin, hematocrit, mean corpuscular hemoglobin [MCH], mean cell hemoglobin concentration [MCHC], total and differential white blood cell count, platelet count. At every visit. Clinical Chemistry: Urea, sodium, potassium, chloride, bicarbonate, creatinine, total bilirubin, ALT, AST, alkaline phosphatase [ALP], serum protein, uric acid, calcium, phosphate. At every visit. Urine testing: at every visit Thyroid function tests: T3, T4 and TSH. At screening, if abnormal results are obtained at screening-week 4, week 48; and at the early discontinuation visit. Anti-peptide antibody test: At screening. HLA-DRB1 at screening * For 15 positive patients, weeks 16 and 20. MS attacks: at all visits from week 4 onwards. Urine pregnancy test: at screening, week -4, at each injection visit, at first follow-up visit (week 20); at early discontinuation visit.

[0178] Statistical methods: No formal sample size calculations and formal interim analyses were performed (no confirmatory statistical tests were performed). P values ​​are presented for descriptive purposes only. The study was exploratory and conclusions were based on the full series of patient evidence.

[0179] Categorical variables were presented using the number of nonmissing observations (n) or number of patients in the population (N) where applicable, and percentages (%). Percentages were rounded to two decimal places. Two-sided 95% confidence intervals (CI) were given where relevant. Continuous variables were described by the number of nonmissing observations (n), arithmetic mean (Mean), standard deviation (SD), minimum, median, Q1–Q3, and maximum.

[0180] Efficacy analyses were based on the PP population (i.e., evaluable patients). Analyses of MRI assessment of brain lesions (proof of principle) were based on the MRI population. All safety analyses were based on the ITT population. Unless otherwise specified, each patient's baseline value shown in the Summary Table was defined as the patient's most recent non-missing assessment for the particular parameter prior to the start of IMP on Study Day 1, including any unscheduled or repeat assessments.

[0181] The ITT population was defined as all patients who received at least one dose of IMP at any time during the study, regardless of whether they met eligibility and other protocol criteria. For the summary of safety endpoints, the safety population is presented as the ITT population. The PP population (evaluable patients) was defined as all ITT patients who were protocol compliant (i.e., had no major protocol violations, met the inclusion / exclusion criteria, received a complete treatment plan, and did not take steroids or other prohibited medications during the treatment phase) up to and including the 20-week visit. The MRI population was defined as the PP population and patients with major violations for PD assessment. The MRI population was used to analyze brain lesions (proof of principle).

[0182] Summary of results Efficacy, MRI In the MRI population of cohort 1, the mean number of new or persistent Gd-enhancing lesions decreased overall from 3.4 (SD: 8.23) at baseline to 2.5 (SD: 4.91) at week 48 / ET; the decrease from baseline to week 16 (0.9 lesions; SD: 1.67) was statistically significant (p = 0.030). These trends were also seen in the ITT population, where the mean number of new or persistent Gd-enhancing lesions decreased statistically significantly from study day 1 (5.0, SD: 9.76) to week 16 (1.2, SD: 1.81; p < 0.001) and increased to 3.2 (SD: 5.33) from week 16 to week 48 / ET. The total volume of Gd-enhancing lesions in cohort 1 also decreased by 304.8 mm at baseline. 3 200.1mm at 48 weeks 3 , -104.8mm 3 decreased overall.

[0183] In cohort 2, the mean number of new or persistent Gd-enhancing lesions was similar from baseline (2.3; SD: 5.47) to week 48 / ET (2.1; SD: 3.63). The increase in the mean number of new or persistent Gd-enhancing lesions from baseline (2.3 lesions) to week 16 (3.5 lesions; SD: 7.09) was statistically significant (p = 0.012) despite the small change in the mean number of lesions. Trends in the cohort 2 ITT population also mirrored trends seen in the cohort 2 MRI population. Although the actual number of lesions seen at both time points was similar (study day 1: 2.1 lesions; SD: 5.25; week 16: 3.2 lesions; SD: 6.80), the increase in the mean number of new or persistent Gd-enhancing lesions was statistically significant (p = 0.010); the mean number of new or persistent lesions decreased from week 16 to week 48 / ET (2.0 lesions, SD: 3.48). The mean total volume of Gd-enhancing lesions in cohort 2 was 188.6 mm compared with baseline (188.6 mm). 3 ) to 48th week (201.0mm 3 ) was about the same (+13.3 mm 3 overall change).

[0184] The mean number of new or newly enlarging T2 hyperintense lesions in cohort 1 (MRI population) was similar from week 8 (5.1 lesions; SD: 8.35) to week 48 (5.2 lesions; SD: 9.44). In cohort 2, the mean number of lesions increased slightly from week 8 (3.5; SD: 7.07) to week 48 (4.1; SD: 6.64).

[0185] The mean cumulative number of new T1 hypointense lesions (assessed only at week 48 compared with baseline) was 7.2 (SD: 12.79) in cohort 1 and 7.8 (SD: 9.21) in cohort 2; the total number of new T1 hypointense lesions at week 48 was 7.5 (SD: 10.87).

[0186] In the MRI population of cohort 1, the proportion of patients without GD-enhancing lesions increased from 52.9% (9 / 17) at study day 1 to 70.6% (12 / 17) at week 48. In cohort 2, the number of patients without GD-enhancing lesions was similar at study day 1 (65.0%, 13 / 20) and week 48 (59.5%, 22 / 37).

[0187] In cohort 1, the proportion of patients free of T2 disease was similar at weeks 28 (52.9%, 9 / 17) and 48 (56.3%, 9 / 16). In cohort 2, the proportion of patients free of T2 disease decreased slightly from weeks 28 (35.0%, 7 / 20) to 48 (27.8%, 5 / 18).

[0188] Patients without T1 lesions were evaluated only at / by week 48. At this time point, 38.2% (13 / 34) of all patients in the MRI population were lesion-free, including 50.0% (8 / 16) of patients in cohort 1 and 27.8% (5 / 18) of patients in cohort 2.

[0189] Safety: Treatment-emergent adverse events Comprehensive overview of treatment-emergent adverse events - ITT population

[0190] [Table 3]

[0191] AEs were defined as treatment-emergent if the onset date was on or after the first dose of ATX-MX-1467 and did not occur after the week 20 visit. Drug-related adverse events were those assessed by the investigator as possibly, probably, or definitely related to study drug, or where no relationship was recorded. AE = adverse event, id = intradermal, IMP = investigational medicinal product, ITT = intent to treat, sc = subcutaneous.

[0192] There were no severe TEAEs; death-related AEs or SAEs; treatment-related SAEs; and no AEs leading to discontinuation or withdrawal from study. There were no antibody responses to any peptide of ATX-MS-1467 in either cohort. Only one patient (2.3%; cohort 1) had an AE leading to drug discontinuation (pruritic skin rash 1 week after 800 μg study drug was administered at week 14). There were no clinically relevant changes seen in on-study laboratory values, vital signs, or Kurtzke function (mean or mean change from baseline). The number of MS relapses was not unexpected for this patient population.

[0193] Only one patient experienced a treatment-emergent SAE (cohort 1; MS relapse; 800 μg at week 17); the event was assessed as not related to ATX-MS-1467.

[0194] Treatment-emergent adverse events by dose - ITT population [Table 4]

[0195] Generally, the greater number of patients reporting TEAEs in Cohort 1 was due to a greater number of injection site reactions. The number of patients reporting AEs tended to be highest at the combined 800 μg dose level, but it is important to note that the combined 800 μg dose includes data from five time points (weeks 8, 10, 12, 14, and 16).

[0196] In cohort 1, the most frequently reported TEAEs at all dose levels were found in the general disorders and administration site conditions SOC, and the most frequently reported TEAE at all dose levels in the preferred term was injection site erythema. Nasopharyngitis was experienced by three patients (14.3%) at the 800 μg dose level only. Multiple sclerosis relapse, experienced by two patients (9.5%), was also seen only at the 800 μg dose level (weeks 14 and 16). There were no other TEAEs in the preferred term reported by more than one patient in cohort 1.

[0197] In cohort 2, the most frequently reported TEAE overall was in the Nervous System Disorders SOC, and the most frequently reported TEAE in the desired time period was headache. Multiple sclerosis relapse was experienced by one patient (4.5%) at the 400 μg dose level and three patients (13.6%) at the 800 μg dose level combined (two patients at week 8 and one patient at week 16). There were no other TEAEs in the desired time period reported by more than one patient in cohort 2.

[0198] Two patients in cohort 1 and three patients in cohort 2 experienced treatment-emergent MS attacks. In cohort 1, both patients experienced MS attacks after treatment with 800 μg. In cohort 2, one patient experienced an MS attack after treatment with 400 μg and three patients after treatment with 800 μg. None of the events were assessed as related to treatment, none of the events had any effect on administration of study medication, and all patients recovered; only one event (cohort 1) was assessed as severe. All attacks were assessed as mild or moderate in severity.

[0199] Treatment-related adverse events The higher number of treatment-related AEs in cohort 1 was driven by the higher number of injection site reactions experienced in this cohort. In cohort 1, the most frequently reported drug-related TEAE across all dose levels was injection site erythema (100 μg: n=8, 38.1%; 800 μg combined: n=9, 42.9%). One patient (4.8%) reported treatment-related fever (50 μg), and one patient reported treatment-related influenza-like illness (100 μg).

[0200] In cohort 2, the most frequently reported drug-related event was also injection site erythema (800 μg combined: n = 3, 13.6%). There were no other drug-related events reported by more than one patient at any dose level in cohort 2. There were no reports of treatment-related fever or influenza-like illness in cohort 2.

[0201] In both cohorts, all treatment-emergent injection site reactions were rated as mild. All TEAEs of influenza-like illness and fever were moderate in severity. No drug-related MS relapses were reported in either cohort.

[0202] Treatment-emergent injection site reactions, Cohort 1-ITT population [Table 5]

[0203] Treatment-emergent injection site reactions, Cohort 2-ITT population [Table 6]

[0204] [Table 7]

[0205] AEs were defined as non-treatment-emergent and treatment-onset if the onset date was after the date of the week 20 visit.

[0206] Drug-related adverse events were those assessed by the investigator as possibly, probably, or definitely related to the study drug, or where no relationship was recorded.

[0207] AE = adverse event, id = intradermal, ITT = intention to treat, sc = subcutaneous

[0208] Following treatment, there were no serious AEs; no AEs or SAEs associated with death; no AEs leading to withdrawal from the study; no injection site reactions; and no treatment-related SAEs.

[0209] Four patients in cohort 1 and four patients in cohort 2 experienced post-treatment relapses of MS; two patients in cohort 1 experienced multiple post-treatment relapses. Two post-treatment relapses experienced by cohort 1 patients were assessed as possibly related to treatment but were not severe. Two patients in cohort 1 experienced post-treatment relapses that were assessed as severe, but neither event was assessed as related to treatment. None of the post-treatment relapses seen in cohort 2 were assessed as related to study treatment. One post-treatment relapse reported by one patient in cohort 2 was assessed as severe. All attacks were assessed as moderate.

[0210] <Example 2> An open-label, single-arm, proof-of-concept study was conducted to evaluate the safety of ATX-MS-1467 (MSC2358825A) and its effect on immune tolerance in subjects with relapsing forms of multiple sclerosis.

[0211] method: This was a multicenter, open-label, Phase IIa study in subjects with relapsing MS. The study consisted of five periods; subjects continued on the study for 48 weeks.

[0212] Screening Period (4 weeks): Subjects were screened to establish initial eligibility prior to entering the baseline control period. Subjects were required to have completed prior treatment with corticosteroids at least 30 days prior to their first MRI scan at visit 2. Subjects who were receiving other unauthorized MS treatments at visit 1 were required to have had human leukocyte antigen (HLA) DRB1 * All such medications were discontinued as soon as possible after confirmation of genotype 15 and study eligibility based on MRI scan at the second visit.

[0213] Baseline control period (8 weeks / 3 visits): Subjects who were HLA positive underwent 3 brain MRI scans (with a minimum of 28 days between successive scans) to determine subject eligibility based on the degree of MRI activity. After confirming subject eligibility for MRI criteria, subjects were able to undergo an optional lumbar puncture for collection of cerebrospinal fluid (CSF). During the baseline control period, subjects did not receive treatment for MS.

[0214] Titration Period (4 weeks / 3 visits): After completion of the baseline control period, eligible subjects entered a titration period in which they received ATX-MS-1467 ID from a starting dose (50 μg) to a maximum dose (800 μg) once every 2 weeks according to the following schedule: Day 1: ATX-MS-1467 50μg ID Day 15: ATX-MS-1467 200μg ID Day 29: ATX-MS-1467 800μg ID.

[0215] Treatment Period (16 weeks / 8 visits): During the treatment period, subjects received ATX-MS-1467 800 μg ID once every 2 weeks for 16 weeks and attended study visits at 2-week intervals for dosing and safety evaluations; additional clinical evaluations, including MRI scans, were performed three times during the treatment period.

[0216] Follow-up period (16 weeks / 4 visits): After completing the treatment period, subjects entered a 16-week follow-up period. During this period, subjects discontinued study treatment and were evaluated for maintenance of any treatment effects. MRI scans were performed three times during the follow-up period.

[0217] Subjects who prematurely discontinued ATX-MS-1467 treatment, ie, withdrew during the titration or treatment period, entered an 8-week safety follow-up period (2 visits).

[0218] Number of targets: At least 15 evaluable subjects were planned for study participation.

[0219] A total of 93 subjects were screened for study participation, and 37 (39.8%) subjects enrolled in the study and began the baseline control period. Nineteen subjects entered and completed the titration period and entered the treatment period. All 19 treated subjects were included in the intention-to-treat (ITT), modified ITT (mITT), and safety analysis sets.

[0220] Diagnosis and main selection criteria: Male and female outpatients aged 18 to 65 years with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) based on the McDonald diagnostic criteria (2010), with clinical evidence of recent MS activity, at least one contrast-enhanced lesion (CEL) on MRI at visit 2, and at least one new CEL between visits 2 and 4, were eligible to participate in the study. Subjects had an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 before the start of study treatment and were HLA-DRB1-positive. * Subjects had to be 15 positive and neurologically stable. Subjects were ineligible for the study if they had primary progressive MS, a renal condition that precluded gadolinium (Gd) administration, a lymphocyte count <500 / μL or a neutrophil count <1500 / μL at the pretreatment visit, or other underlying medical condition that precluded study participation.

[0221] Beta interferon, plasma exchange, or intravenous gamma globulin within 8 weeks prior to Study Day 1; steroids or adrenocorticotropic hormone within 30 days prior to the MRI scan at Visit 2; or previous treatment with glatiramer acetate, cytotoxic agents, fingolimod, laquinimod, teriflunomide, total body lymphatic irradiation, stem cell or bone marrow transplantation, monoclonal antibody therapy, dimethyl fumarate, zirconate, any disease-related T-cell vaccine, or peptide tolerizing agents for treatment of MS were not permitted.

[0222] Test product: Dose and mode of administration, batch number: The study drug was ATX-MS-1467, administered ID once every 2 weeks for a total of 20 weeks, starting at a dose of 50 μg and increasing over 4 weeks to a final dose of 800 μg. Individual batch numbers are available upon request.

[0223] Treatment duration: The maximum duration of study participation, from visit 1 to visit 19, was 48 weeks. The duration of study treatment was 20 weeks.

[0224] Reference treatment, dose and mode of administration, batch number: Not applicable.

[0225] Evaluation criteria: Efficacy: The primary endpoint was the change in the mean number of T1 CELs in the last three on-treatment scans (weeks 12, 16 and 20) compared with the mean number of T1 CELs in the three baseline scans (visits 2, 3 and 4).

[0226] Secondary endpoints included: ·MRI Total number of T1 CELs at each scheduled post-baseline MRI visit Change from baseline (average of 3 baseline scans, visits 2, 3, and 4) in total T1 CELs at each scheduled post-baseline MRI visit Change from baseline (average of 3 baseline scans, 2nd, 3rd, and 4th visits) in total T1 CEL volume at each scheduled post-baseline MRI visit Total number of new or newly enlarging T2 lesions at each scheduled post-baseline MRI visit Change in total T1 CELs from visit 4 at each scheduled post-baseline MRI visit Change from visit 4 in total T1 CEL volume at each scheduled post-baseline MRI visit ·Clinical Mean annualized relapse rate (ARR) at 20 weeks Time to first recurrence Change from baseline in total EDSS score at week 20 - Change from baseline in total Multiple Sclerosis Functional Composite (MSFC) score at week 20.

[0227] The following exploratory endpoints were also considered: Maintenance of effect of ATX-MS-1467 on MRI parameters after treatment cessation at 28 and 36 weeks in a subgroup of responders Time course of immunological markers (e.g., cytokines, antibodies) in peripheral blood / peripheral blood mononuclear cells (PBMCs) and CSF - Changes in disease markers (e.g., OCB, immunoglobulin G [IgG] indicators, demyelination) in peripheral blood and CSF over time Serum anti-peptide antibody levels at weeks 11, 20 and 24 Time course of MBP-induced PBMC proliferation Change from baseline in MBP-induced PBMC proliferation at week 20 Change from week 20 in MBP-induced PBMC proliferation at week 36 / end of study.

[0228] Safety: Safety endpoints included: The nature, frequency, and severity of treatment-emergent adverse events (TEAEs) The frequency and severity of injection site reactions Frequency and timing of vital sign measurements, physical examination findings, clinical laboratory variables, electrocardiograms, and premature study termination.

[0229] Statistical methods: The sample size for this study was based on three assumptions: (1) a treatment effect of 70% reduction in the number of CELs compared to the mean number of CELs in the three baseline scans; (2) the mean number of CELs at baseline is 5 with a standard deviation (SD) of 6; and (3) the mean number of CELs during the post-treatment period (weeks 24-36) is 1.5 with a SD of 1.8. Using a two-sided 5% level, >80% and >90% of the mock studies showed statistically significant results with sample sizes of 12 and 14 subjects, respectively. Therefore, a sample size of 15 subjects was selected.

[0230] Except for the evaluation of maintenance of response, which was performed using the responder population, and the safety analyses, which were based on the safety population, analyses of the primary and secondary endpoints were based on the mITT population. Responders were defined as subjects who achieved a ≥60% reduction in the number of T1 Gd-enhancing lesions at week 20 (average of the last three on-treatment scans at weeks 12, 16, and 20) from baseline (average of the three baseline scans at visits 2, 3, and 4).

[0231] The primary endpoint was analyzed using the nonparametric Wilcoxon signed-rank test for testing location change due to treatment effect, based on the exact distribution of the signed-rank statistic, where the distribution is a convolution of a scaled binomial distribution. Ancillary analyses were performed to estimate the mean percentage reduction in new T1 Gd-enhancing lesions during the treatment period compared with the baseline control period, using generalized estimating equation (GEE) linear regression models with negative binomial and Poisson link functions.

[0232] The same nonparametric procedures used for the primary efficacy endpoint were performed based on new T1 Gd-enhancing lesions. Descriptive statistics were presented for the secondary endpoints at each visit that fell into the mITT analysis set.

[0233] Continuous variables were summarized descriptively using number of observations, mean, SD, 95% confidence interval (CI), median, minimum and maximum values. Categorical variables were summarized using frequency counts and percentages. Time to event variables were presented as Kaplan Meier plots, median survival and 95% CI.

[0234] Summary and conclusions: Subject Disposition: There were 93 subjects screened for study participation; 37 (39.8%) subjects were enrolled. Nineteen (51.4%) subjects entered and completed the titration period, and 18 (48.6%) subjects completed the treatment period. One subject (2.7%) discontinued the investigational medicinal product (IMP) due to an adverse event (AE) of diarrhea. Another subject (2.7%) withdrew consent after completing the treatment period. All 19 eligible subjects were included in the ITT, mITT, and safety analysis sets. Seven subjects who demonstrated a ≥ 60% reduction from baseline in T1 Gd-enhancing lesion counts at week 20 were included in the responder analysis set.

[0235] Demographics and baseline characteristics The mean age of subjects in the study was 27.1 years (range 19-38 years), with the majority of subjects <30 years (73.7%). Most subjects were female (78.9%), and all subjects were Caucasian. All 19 subjects had a diagnosis of RRMS, and the majority of subjects (89.5%) reported 1-2 relapses in the 24 months prior to the second visit. The median EDSS score at baseline was 2.00 (range 1.5-3.5). The median MSFC score at baseline based on the National Multiple Sclerosis Society (NMSS) reference population was 0.470 (range -0.95-1.21). The mean number and volume of T1 Gd-enhancing lesions were 7.4 (range 1-31) and 0.838 mL (range 0.05-3.65 mL), respectively.

[0236] Efficacy Results: Based on nonparametric analysis using the mITT analysis set, the mean number of T1 Gd-enhancing lesions during treatment (weeks 12, 16, and 20) was statistically significantly reduced compared to baseline (p = 0.0143). The Hodges-Lehmann estimate (95% CI) of location change was -1.3 (-6.3, 0.0). Similarly, the mean number of new T1 Gd-enhancing lesions was statistically significantly reduced (p = 0.0106). The Hodges-Lehmann estimate (95% CI) of location change was -1.3 (-5.7, 0.0). The results of the supplementary analysis of new T1 Gd-enhancing lesions were consistent with the primary analysis.

[0237] Numerical reductions from baseline in the mean number and volume of T1 Gd-enhancing lesions were observed at all post-treatment assessments. The mean number of lesions at baseline was 7.4 (range 1 to 31), and the mean change from baseline in lesion number was -4.6 to -1.6. The mean lesion volume at baseline was 0.838 mL (range 0.05 to 3.65 mL), and the mean change from baseline in lesion volume was -0.579 to -0.225 mL. Similarly, numerical reductions in the mean T1 Gd-enhancing lesions and volumes were observed from week 0 to each post-treatment assessment. The mean change from week 0 in lesion number was -3.5 to -0.9, and the mean change from week 0 in lesion volume was -0.473 to -0.157 mL. The median number of new T1 Gd-enhancing lesions was similar from week 12 (1.5) to the end of the study (0.0 at week 28 to 2.0 at the end of the study). The median number of new / enlarging T2 lesions decreased from 8.0 (range 0-89) at week 12 to 1.0 (range 0-20) at week 16, with the median number ranging from 1.0 to 3.0 at subsequent visits.

[0238] A single relapse occurred during study treatment in three (15.8%) subjects; no on-treatment relapses were reported for the remaining 16 subjects. The estimated mean ARR was 2.60. For these three subjects, relapse onset occurred on days 50, 59, and 89, and the Kaplan-Meier estimate of the probability of not experiencing a relapse decreased from 1.00 at week 4 to 0.84 at week 20.

[0239] The change in EDSS score from baseline to the end-of-treatment visit was not statistically significant.Similarly, the change in MSFC score from baseline to the end-of-treatment visit was not statistically significant when baseline values ​​from enrolled subjects or values ​​from the NMSS Task Force database were used as reference.

[0240] For 4 of 7 (57.1%) potential responders, the mean percentage of maintained treatment response was ≧85%.

[0241] Safety Results: Overall, 78.9% of subjects reported at least one TEAE during the study; TEAEs in 57.9% of subjects were assessed as related to IMP. The most frequently reported TEAEs were injection site erythema (26.3%), headache (21.1%), and nasopharyngitis (15.8%).

[0242] No deaths, serious TEAEs, or TEAEs of severe intensity were reported. One subject discontinued IMP due to a TEAE of diarrhea, which was assessed as long-lasting, moderate in intensity, and related to IMP.

[0243] For most subjects, the onset of TEAEs was <26 days from initiation of IMP.

[0244] All injection site reactions during the study (36.8% of subjects) were mild in severity, with the most frequently reported symptoms being erythema, pruritus, and induration.

[0245] Three subjects had weight loss of ≧7% during the study; there were otherwise no clinically relevant changes in laboratory tests, vital signs, or electrocardiogram parameters.

[0246] Conclusion: The median reduction in T1 Gd-enhancing lesions during the treatment period compared with the baseline control period was statistically significant (p = 0.0143) based on the nonparametric Wilcoxon signed-rank test. The Hodges-Lehmann estimate (95% CI) of location change was -1.3 (-6.3, 0.0).

[0247] Ancillary analyses using negative binomial and Poisson GEE models yielded consistent conclusions. The mean percentage reduction in new T1 Gd-enhancing lesions during the treatment period compared with the baseline control period was statistically significant (p-value = 0.0109). The mean percentage reduction (95% CI) estimated by GEE using the negative binomial model was 38.4% (10.6%, 57.6%).

[0248] Numerical reductions from baseline and week 0 in mean T1 Gd-enhancing lesion number and volume were observed at all post-treatment assessments.

[0249] The median number of new / enlarging T2 lesions decreased from 8.0 at week 12 to 1.0 at week 16 and ranged from 1.0 to 3.0 at subsequent visits.

[0250] Only a minority of subjects (15.8%) experienced a relapse during the study. The Kaplan-Meier estimated probability of being free of a relapse by week 20 is 0.84.

[0251] There were no statistically significant changes in EDSS or MSFC scores from baseline to the end-of-treatment visit.

[0252] For the seven subjects considered responders, the mean percentage of maintained treatment effect was ≧50%; however, three of these subjects had extremely low baseline lesion counts and therefore achieved a 100% reduction.

[0253] No safety or tolerability concerns were identified following treatment with ATX-MS-1467 800 μg administered ID every 2 weeks.

[0254] <Example 3> The results of the two studies in Examples 1 and 2 were compared. As shown in Figures 1 and 2, new lesions were significantly reduced, confirming efficacy in both studies. However, Figure 1 shows that the dose escalation schedule is important to maximize efficacy. The longer dose escalation used in the first study resulted in a 78% reduction in the number of new lesions, whereas Figure 2 shows that the shorter dose escalation schedule used in the second study did not result in this level of reduction. On the other hand, Figure 2 shows that repeated treatment at the maximum dose (800 μg) prolonged efficacy. Therefore, for maximum efficacy, the longer dose escalation of the first study should be used in combination with the longer treatment at the maximum dose used in the second study.

[0255] <Example 4> A safety and proof-of-principle study of ATX-GD-59 in male and female subjects with Graves' disease and not currently treated with antithyroid therapy: an open-label study with escalating dose levels over five administered by intradermal injection.

[0256] method: HLA-DRB1 * 15. HLA-DRB1 * 03 and / or HLA-DRB1 * An open-label, dose-escalation evaluation of the safety, tolerability, and efficacy of ATX-GD-59 in approximately 12 evaluable subjects with Graves' disease who are 04-positive and not currently treated with antithyroid therapy.

[0257] "ATX-GD-59" as described herein includes the RNB-5D-K1 and RNB-9B peptides of SEQ ID NOs:5 and 6.

[0258] The first four subjects were recruited in sequential order, with a minimum of 48 hours between each subject's first dose. Once the first subject had received their second dose and no safety concerns were identified, dosing began on the remaining subjects.

[0259] ATX-GD-59 was titrated at five dose levels (25, 50, 100, 400 and 800 μg injections) followed by five additional injections of 800 μg, all doses based on total peptide.

[0260] All doses were administered by intradermal injection at 14+ / -3 day intervals.

[0261] Selection Criteria 1. Diagnosis of Graves' disease as assessed by a physician based on clinical and laboratory findings and no antithyroid treatment. 2. Quantifiable levels of TSHR antibodies. 3. Elevated levels of free T3 and / or free T4 (not exceeding 15 pmol / L and 35 pmol / L, respectively) including undetectable levels of thyroid stimulating hormone. 4. HLA-DRB1 * 15. HLA-DRB1 * 03 and / or HLA-DRB1 * 04 positive. 5. Age 18 to 65 at the time of informed consent. 6. Subject must be willing and able to provide written informed consent and willing to comply with the protocol assessments / procedures. 7. Male subjects must be infertile (biologically or surgically) or committed to using a reliable method of birth control for the duration of the study and until at least 90 days after the last dose of ATX-GD-59. 8. Women of childbearing age are eligible: - not be pregnant, breastfeeding or attempting to become pregnant, and - Must use highly effective contraception, as defined below, for the entire duration of the study and for at least 90 days after the last dose of ATX-GD-59

[0262] Exclusion criteria 1. Subjects who are pregnant or breastfeeding, and / or in the postpartum period. 2. History of any reaction or hypersensitivity reaction that, in the opinion of the Investigator, precludes the subject from participating in the study. 3. Treatment with any antithyroid medication, e.g., carbimazole, within the past 3 months prior to Study Day 1. 4. Previous treatment with radioactive iodine or thyroidectomy (partial or total). 5. Evidence of moderate or severe orbital disease including optic nerve compression requiring steroids and / or clinical activity score >3. 6. Large, compressible goiter causing localized symptoms such as difficulty swallowing or breathing. 7. Treatment with steroids (administered by oral and / or parenteral routes) or adrenocorticotropic hormones, except for inhaled steroids, within 3 months prior to Study Day 1. 8. Symptoms and signs of thyroid storm, such as confusion and fever, that have no other cause than hyperthyroidism. 9. Significant cardiac disease requiring emergency treatment for thyrotoxicosis and / or atrial fibrillation. 10. Previous treatment with biologic or peptide-based therapy, including rituximab. 11. Previous use of a disease-related T-cell vaccine or peptide tolerizing agent to treat Graves' disease. 12. Detectable levels of antibodies in plasma specific for any peptide within ATX-A, significant drug allergy history. 13. Use of any investigational medication or participation in any clinical trial within 3 months prior to Study Day 1. 14. Treatment with any cytokine or anti-cytokine therapy within 3 months prior to Study Day 1. 15. Inadequate liver function as defined by total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase >3 times the upper limit of normal at the screening visit. 16. Subjects with significant medical illness or psychiatric condition that, in the opinion of the Investigator, precludes participation in the study or impairs ability to provide informed consent; any other clinically evident autoimmune disease. 17. Clinically significant illness as determined by the investigator within 4 weeks prior to the first dose of ATX-GD-59 (Study Day 1). 18. History of active or chronic infectious disease or any disease that impairs immune function (e.g., HIV+, HTLV-1, Lyme disease, latent or active TB, hepatitis). 19. Major surgery within 4 weeks prior to screening visit. 20. Known osteoporosis or metabolic bone disease.

[0263] 21. Withdrawal Criteria 22. Subject experiences a serious or severe adverse event that prevents him / her from continuing. 23. The subject commits a significant protocol violation where continuing in the study would pose an increased risk to the subject. 24. Subject requests early discontinuation. 25. At the request of the investigator or sponsor (e.g., if it is believed that the subject's health would be compromised by continuing in the study or that the subject is unwilling or unable to comply with the protocol or study procedures). 26. Subject becomes unobservable. 27. Subject requires treatment that is prohibited by the exclusion criteria or protocol. 28. The subject exhibits a strong and increased positive response in anti-drug antibody assays to any peptide of ATX-GD-59, accompanied by clinical signs of adverse immune reactions, which may be unexplained chills, fever or flu-like symptoms following treatment with ATX-GD-59. 29. The subject becomes pregnant. 30. GD-59 at screening visit.

[0264] Management of thyrotoxicosis during the study Symptomatic patients may be treated with propranolol (up to 160 mg per day) adjusted to control tachycardia or other symptoms. If alternative beta-adrenergic receptor blockade is required, this must be agreed with the Study Medical Monitor. If there is a contraindication to the use of beta-blockers (e.g., asthma), a rate limiting calcium channel blocker (e.g., diltiazem MR, 120-240 mg daily) may be used instead. This must also be agreed with the study medical monitor.

[0265] Indicate administration of antithyroid medication during the study if: Subject has trigger levels of Free T3 (>20 pM) and / or Free T4 (>45 pM) on 2 consecutive scheduled or unscheduled visits. Sustained weight loss of >5 kg from baseline (study day 1). Sustained tachycardia >120 bpm. · Serious cardiac events requiring emergency treatment for thyrotoxicosis. If the investigator or treating physician believes it is appropriate to administer antithyroid medication at any time during the study.

[0266] Treatment duration: The study consisted of a screening visit, an 18-week treatment period, an efficacy assessment four weeks after the last dose, and an eight-week follow-up period.

[0267] Dosage and Mode of Administration: ATX-GD-59 is a lyophilized equimolar mixture of two peptides that is reconstituted in the clinic prior to intradermal injection to give one of two different concentrations for injection depending on the dose.

[0268] Dose strength: Total peptide content of 4mg / mL and 0.5mg / mL when reconstituted with water for injection and 0.9% saline, respectively.

[0269] Safety Monitoring and Analysis: Subjects will be observed in the clinic for at least 2 hours after administration of study medication, with vital signs recorded at 15 minute intervals for the first hour and at 30 minute intervals for the next hour. If the subject is well (in the investigator's opinion), the subject will be allowed to leave the clinic. A contact card with an emergency telephone number will be provided to each subject.

[0270] Subjects are given a take-home diary to record any injection site reactions for at least 24 hours following study drug injection.

[0271] The first four subjects will be recruited in sequence, with a minimum of 48 hours between each subject's first dose. Safety data for each subject will be reviewed by the investigator and sponsor or sponsor's representative after the first ATX-GD-59 dose, and thereafter between the second (week 10) and third (week 12) 800 μg doses. Dosing of the remaining subjects will begin only if the first subject has received the second 50 μg dose (week 2) and no safety concerns have been identified.

[0272] For the first five subjects, the combined individual subject safety data will be reviewed by the investigator and the sponsor or sponsor's representative after the second 800 μg dose (at week 10) and prior to the third 800 μg dose (at week 12).

[0273] The combined safety data for the first five subjects will be subject to interim review by the Data Monitoring Committee (DMC) following administration of the final 800 μg dose (week 18).

[0274] Primary Objective The primary endpoint of this study is a safety assessment to ensure, first and foremost, that exposure to the study drug via the intradermal route of administration will not harm the Graves' disease affected population.

[0275] Safety endpoints, assessed continuously through 22 weeks, included: Injection site reactions as reported by subjects on diary cards. - The occurrence of treatment-related adverse events, serious adverse events, and laboratory abnormalities compared to baseline. Physical exam results and vital signs (reported continuously and compared to baseline / screening). Early termination of treatment and / or study and reasons for early termination.

[0276] Evaluation criteria for secondary objectives: ·TSHR antibody levels. · The ratio of stimulatory to inhibitory TSHR antibodies. ·Free T3, Free T4 and TSH serum levels.

[0277] Exploratory objectives evaluation criteria: ·TSHR-induced PBMC T cell activity. T cell cytokine signature. ·IL-10 pathway and related genes (mRNA).

[0278] Dosage regimen: [Table 8]

[0279] result Safety data from the first five patients were analyzed by the DMC. No safety issues were identified.

[0280] Additionally, free T3 and TSHR Ab levels (TRAB) data showed: Three of five subjects had a decrease in T3 and TRAB All subjects had a decrease in stimulatory TRAB levels (TSI) There was a strong correlation (0.92) between the percent change in free T3 and TRAB. There was an excellent correlation (0.84) between the % change in free T3 and TSI.

[0281] [Table 9]

[0282] All publications mentioned herein are incorporated herein by reference. Various modifications and variations of the described methods and uses of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain preferred embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art of molecular biology, immunology, or related fields are intended to be within the scope of the claims. Sequence Listing <110> WORG PHARMACEUTICALS (HANGZHOU) CO., LTD. <120> THERAPEUTIC METHOD USING TOLEROGENIC PEPTIDES <130> PA22-576 <150> GB 1700111.6 <151> 2017-01-04 <160> 6 <170> PatentIn version 3.5 <210> 1 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 1 Pro Arg His Arg Asp Thr Gly Ile Leu Asp Ser Ile Gly Arg Phe 1 5 10 15 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptide <400> 2 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr 1 5 10 15 Pro <210> 3 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptide <400> 3 Ala Ser Asp Tyr Lys Ser Ala His Lys Gly Phe Lys Gly Val Asp 1 5 10 15 <210> 4 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptide <400> 4 Gly Phe Lys Gly Val Asp Ala Gln Gly Thr Leu Ser Lys Ile Phe 1 5 10 15 <210> 5 <211> 21 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptide <400> 5 Lys Lys Lys Lys Tyr Val Ser Ile Asp Val Thr Leu Gln Gln Leu Glu 1 5 10 15 Ser His Lys Lys Lys 20 <210> 6 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptide <400> 6 Gly Leu Lys Met Phe Pro Asp Leu Thr Lys Val Tyr Ser Thr Asp 1 5 10 15

Claims

1. 1. A pharmaceutical composition comprising a tolerogenic peptide or a combination of tolerogenic peptides for use in a method for treating or preventing a disease in a subject, the method comprising administering to a subject a dose of: Day 1: first dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600–1500 μg; Day 126 ± 7: 10th dose of about 600-1500 μg; and 140 days ± 7: 11th dose of approximately 600–1500 μg administering to a subject a tolerogenic peptide or a combination of tolerogenic peptides in a dose escalation protocol at (a) the disease is multiple sclerosis or optic neuritis and the tolerogenic peptide is MBP 30-44 (SEQ ID NO:1), MBP83-99 (SEQ ID NO:2), MBP131-145 (SEQ ID NO:3), or MBP140-154 (SEQ ID NO:4), and the combination of tolerogenic peptides is two, three, or all four of MBP 30-44 (SEQ ID NO:1), MBP83-99 (SEQ ID NO:2), MBP131-145 (SEQ ID NO:3), and MBP140-154 (SEQ ID NO:4); or (b) the disease is Graves' disease, the tolerogenic peptide is RNB-5D-K1 (SEQ ID NO: 5) or RNB-9B (SEQ ID NO: 6), and the combination of tolerogenic peptides is RNB-5D-K1 (SEQ ID NO: 5) and RNB-9B (SEQ ID NO: 6); Pharmaceutical compositions.

2. 2. The pharmaceutical composition of claim 1, wherein the first dose is about 25 μg.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the second dose is about 50 μg.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the third dose is about 100 μg.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the fourth dose is about 400 μg.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein a 12th dose of about 600 to 1500 μg is administered on day 154±7.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein a thirteenth dose of about 600 to 1500 μg is administered on day 168±7.

8. 8. The pharmaceutical composition of any one of claims 1 to 7, wherein the fifth, sixth, seventh, eighth, nineth and tenth, and optionally the eleventh, twelfth and thirteenth doses are each about 800 μg.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the administration of the tolerogenic peptide or the combination of tolerogenic peptides is intradermal.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the subject is a human.

11. 1. Use of a tolerogenic peptide or a combination of tolerogenic peptides in the manufacture of a medicament for use in the treatment or prevention of a disease, said medicament comprising the following doses: Day 1: first dose of about 15 to about 40 μg; Day 14 ± 7: second dose of approximately 35–65 μg; Day 28 ± 7: third dose of approximately 80–120 μg; Day 42 ± 7: Fourth dose of approximately 300–500 μg; Day 56 ± 7: 5th dose of approximately 600–1500 μg; Day 70 ± 7: 6th dose of approximately 600–1500 μg; Day 84 ± 7: 7th dose of approximately 600–1500 μg; Day 98 ± 7: 8th dose of approximately 600–1500 μg; Day 112 ± 7: 9th dose of approximately 600–1500 μg; Day 126 ± 7: 10th dose of about 600-1500 μg; and 140 days ± 7: 11th dose of approximately 600–1500 μg and for administration by a dose escalation protocol at (a) the disease is multiple sclerosis or optic neuritis and the tolerogenic peptide is MBP 30-44 (SEQ ID NO:1), MBP83-99 (SEQ ID NO:2), MBP131-145 (SEQ ID NO:3), or MBP140-154 (SEQ ID NO:4), and the combination of tolerogenic peptides is two, three, or all four of MBP 30-44 (SEQ ID NO:1), MBP83-99 (SEQ ID NO:2), MBP131-145 (SEQ ID NO:3), and MBP140-154 (SEQ ID NO:4); or (b) the disease is Graves' disease, the tolerogenic peptide is RNB-5D-K1 (SEQ ID NO: 5) or RNB-9B (SEQ ID NO: 6), and the combination of tolerogenic peptides is RNB-5D-K1 (SEQ ID NO: 5) and RNB-9B (SEQ ID NO: 6); use.

12. Use of a tolerogenic peptide or a combination of tolerogenic peptides in the manufacture of a medicament according to claim 11, (i) the dose of the tolerogenic peptide or the combination of tolerogenic peptides is as defined in any one of claims 2 to 8, and / or (ii) the administration of the tolerogenic peptide or combination of tolerogenic peptides is intradermal; and / or (iii) the subject is a human; use.

Citation Information

Patent Citations

  • Composition

    JP2018502093A